<DOC>
	<DOCNO>NCT00001006</DOCNO>
	<brief_summary>To determine toxic effect AS-101 various dos patient AIDS AIDS relate complex . Also determine effect various dose AS-101 immune function occurrence infection patient . AIDS viral disease characterize loss immune function development frequent , eventually fatal , infectious disease . Although zidovudine ( AZT ) prolong survival patient AIDS , AZT quite toxic need effective less toxic drug . AS-101 synthetic organic compound contain metal tellurium test laboratory study improve immune function .</brief_summary>
	<brief_title>A Study AS-101 Patients With AIDS AIDS Related Complex ( ARC )</brief_title>
	<detailed_description>AIDS viral disease characterize loss immune function development frequent , eventually fatal , infectious disease . Although zidovudine ( AZT ) prolong survival patient AIDS , AZT quite toxic need effective less toxic drug . AS-101 synthetic organic compound contain metal tellurium test laboratory study improve immune function . Patients give intravenous infusion AS-101 3 time week 12 week . The first group 6 patient receives dose cause toxic effect preliminary study . If adverse effect occur , next 6 patient receive high dose level , optimum dose reach . The investigator determine optimum dose base type severity adverse effect experience patient study effect drug immune function patient effect HIV infection . Samples blood urine take periodically study skin test perform 3 time aid evaluation AS-101 . Patients receive standard treatment infection develop study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Inhaled pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Ketoconazole . Standard outpatient therapy infection develop trial . Oral acyclovir 7 day . Patients must : Antibody HIV ELISA . AIDS AIDS relate complex ( ARC ) . T4 cell count &lt; 400 cells/mm3 2 determination least 72 hour apart . Prior Medication : Allowed : Inhaled pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Ketoconazole . Oral acyclovir 7 day . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection malignancy require concurrent treatment . Serious medical problem , diabetes , renal disease , ASHD , hypertension , would complicate interpretation treatment result . Transfusion requirement exceed 2 transfusion per month order achieve hemoglobin &gt; 9 g/dl . Concurrent Medication : Excluded : Treatment active opportunistic infection malignancy . Systemic antiviral preparation . Immunosuppressive agent . Immunostimulation therapy . Specific therapy Kaposi 's sarcoma malignancy . Concurrent Treatment : Excluded : More 2 unit red blood cell transfusion per month order achieve hemoglobin &gt; 8 g/dl . Patients unlikely unable , reason distance hospital psychological consideration , comply requirement protocol , especially regard regular attendance treatment , exclude . Prior Medication : Excluded : Systemic antiviral preparation . Isoprinosine . Excluded 1 month study entry : Immunosuppressive agent . Immunomodulators . Prior Treatment : Excluded : Immunostimulation therapy , BCG vaccine . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Immunologic Surveillance</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>ammonium trichloro ( dioxoethylene-O , O'- ) tellurute</keyword>
</DOC>